Association between inflammatory bowel disease and Vitamin D deficiency: A systematic review and meta-analysis

Inflammatory Bowel Diseases

Volumn 21, Issue 11, 2015, Pages 2708-2717

  Del Pinto, Rita ^a,b   Pietropaoli, Davide ^a,b   Chandar, Apoorva K ^b,c   Ferri, Claudio ^a   Cominelli, Fabio ^b,c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Crohn's disease; inflammatory bowel disease; meta analysis; ulcerative colitis; Vitamin D

Indexed keywords

VITAMIN D; 25-HYDROXYVITAMIN D;

DISEASE ASSOCIATION; DISEASE DURATION; HUMAN; INFLAMMATORY BOWEL DISEASE; LATITUDE; LONGITUDINAL STUDY; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; VITAMIN D DEFICIENCY; ANALOGS AND DERIVATIVES; BLOOD; INFLAMMATORY BOWEL DISEASES; ODDS RATIO;

HUMANS; INFLAMMATORY BOWEL DISEASES; OBSERVATIONAL STUDIES AS TOPIC; ODDS RATIO; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84945248982     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000546     Document Type: Review

References (90)

1. Burisch J, Munkholm P. Inflammatory bowel disease epidemiology. Curr Opin Gastroenterol. 2013;29:357-362.
2. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol. 2013;5:237-247.
3. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54 e42; quiz e30.
4. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol. 2009;104:2100-2109.
5. Bernklev T, Jahnsen J, Aadland E, et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand J Gastroenterol. 2004;39:365-373.
6. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
7. Gunnarsson C, Chen J, Rizzo JA, et al. Direct health care insurer and outof-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57:3080-3091.
8. Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol. 2007;23:365-369.
9. Ananthakrishnan AN. Environmental risk factors for inflammatory bowel diseases: a review. Dig Dis Sci. 2015;60:290-298.
10. Hold GL, Smith M, Grange C, et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol. 2014;20:1192-1210.
11. Gentschew L, Ferguson LR. Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol Nutr Food Res. 2012;56:524-535.
12. Cornish JA, Tan E, Simillis C, et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-Analysis. Am J Gastroenterol. 2008;103:2394-2400.
13. Molodecky NA, Panaccione R, Ghosh S, et al. Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:1792-1799.
14. Rampton DS. The influence of stress on the development and severity of immune-mediated diseases. J Rheumatol Suppl. 2011;88:43-47.
15. Cominelli F. Cytokine-based therapies for Crohn's disease-new paradigms. N Engl J Med. 2004;351:2045-2048.
16. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol. 2008;14:390-400.
17. Ardizzone S, Cassinotti A, Trabattoni D, et al. Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int J Immunopathol Pharmacol. 2009;22:63-71.
18. Di Rosa M, Malaguarnera G, De Gregorio C, et al. Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cell Immunol. 2012;280:36-43.
19. Cantorna MT, Munsick C, Bemiss C, et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130:2648-2652.
20. Lagishetty V, Misharin AV, Liu NQ, et al. Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis. Endocrinology. 2010;151:2423-2432.
21. Kong J, Zhang Z, Musch MW, et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2008;294:G208-G216.
22. Cantorna MT, Zhu Y, Froicu M, et al. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004; 80:1717S-1720S.
23. Abraham BP, Prasad P, Malaty HM. Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. Dig Dis Sci. 2014;59:1878-1884.
24. Farraye FA, Nimitphong H, Stucchi A, et al. Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn's disease. Inflamm Bowel Dis. 2011;17:2116-2121.
25. Xue LN, Xu KQ, Zhang W, et al. Associations between vitamin D receptor polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-Analysis. Inflamm Bowel Dis. 2013;19:54-60.
26. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology. 2012;142:482-489.
27. Gilman J, Shanahan F, Cashman KD. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1007-1016.
28. Hadj Taieb S, Kallel L, FekiM, et al. Unbalanced bone remodeling in Tunisian patients with inflammatory bowel diseases. Tunis Med. 2013;91:273-277.
29. McCarthy D, Duggan P, O'Brien M, et al. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment Pharmacol Ther. 2005;21:1073-1083.
30. El-Hodhod MA, Hamdy AM, Abbas AA, et al. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol. 2012;12:44.
31. Souza HN, Lora FL, Kulak CA, et al. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density [in Portuguese]. Arq Bras Endocrinol Metabol. 2008;52:684-691.
32. Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:42-50.
33. Driscoll RH Jr, Meredith SC, Sitrin M, et al. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology. 1982;83:1252-1258.
34. de Bruyn JR, van Heeckeren R, Ponsioen CY, et al. Vitamin D deficiency in Crohn's disease and healthy controls: a prospective case-control study in the Netherlands. J Crohns Colitis. 2014;8:1267-1273.
35. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med. 1996;239:131-137.
36. Tan B, Li P, Lv H, et al. Vitamin D levels and bone metabolism in Chinese adult patients with inflammatory bowel disease. J Dig Dis. 2014;15:116-123.
37. Garg M, Rosella O, Lubel JS, et al. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2634-2643.
38. Jorgensen SP, Hvas CL, Agnholt J, et al. Active Crohn's disease is associated with low vitamin D levels. J Crohns Colitis. 2013;7:e407-e413.
39. Prosnitz AR, Leonard MB, Shults J, et al. Changes in vitamin D and parathyroid hormone metabolism in incident pediatric Crohn's disease. Inflamm Bowel Dis. 2013;19:45-53.
40. Duggan P, O'Brien M, Kiely M, et al. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am J Gastroenterol. 2004;99:2178-2185.
41. Dumitrescu G, Mihai C, Dranga M, et al. Serum 25-hydroxyvitamin D concentration and inflammatory bowel disease characteristics in Romania. World J Gastroenterol. 2014;20:2392-2396.
42. El-Matary W, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci. 2011;56:825-829.
43. Joseph AJ, George B, Pulimood AB, et al. 25 (OH) vitamin D level in Crohn's disease: association with sun exposure & disease activity. Indian J Med Res. 2009;130:133-137.
44. Abreu MT, Kantorovich V, Vasiliauskas EA, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut. 2004;53:1129-1136.
45. Suibhne TN, Cox G, Healy M, et al. Vitamin D deficiency in Crohn's disease: prevalence, risk factors and supplement use in an outpatient setting. J Crohns Colitis. 2012;6:182-188.
46. Tajika M, Matsuura A, Nakamura T, et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol. 2004;39:527-533.
47. Alkhouri RH, Hashmi H, Baker RD, et al. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56:89-92.
48. Grunbaum A, Holcroft C, Heilpern D, et al. Dynamics of vitamin D in patients with mild or inactive inflammatory bowel disease and their families. Nutr J. 2013;12:145.
49. Ardizzone S, Bollani S, Bettica P, et al. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med. 2000;247:63-70.
50. Laakso S, Valta H, Verkasalo M, et al. Impaired bone health in inflammatory bowel disease: a case-control study in 80 pediatric patients. Calcif Tissue Int. 2012;91:121-130.
51. Vazquez MA, Lopez E, Montoya MJ, et al. Vertebral fractures in patients with inflammatory bowel disease compared with a healthy population: a prospective case-control study. BMC Gastroenterol. 2012;12:47.
52. Salacinski AJ, Regueiro MD, Broeder CE, et al. Decreased neuromuscular function in Crohn's disease patients is not associated with low serum vitamin D levels. Dig Dis Sci. 2013;58:526-533.
53. Veit LE, Maranda L, Fong J, et al. The vitamin D status in inflammatory bowel disease. PLoS One. 2014;9:e101583.
54. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269, W64.
55. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
56. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96:1911-1930.
57. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses [Ottawa Hospital Research Institute Web site]. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed April 25, 2015.
58. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Volume 2014. The Cochrane Collaboration; 2011.
59. Viechtbauer W. Conducting meta-Analyses in R with the metafor package. J Stat Softw. 2010;36:1-48.
60. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5:299-314.
61. Hanley DA, Davison KS. Vitamin D insufficiency in North America. J Nutr. 2005;135:332-337.
62. Mouli VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;39:125-136.
63. Palmer MT, Weaver CT. Linking vitamin d deficiency to inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2245-2256.
64. Cantorna MT. Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch Biochem Biophys. 2012;523:103-106.
65. Pinzone MR, Di Rosa M, Celesia BM, et al. LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. Eur Rev Med Pharmacol Sci. 2013;17:1938-1950.
66. Wu S, Liao AP, Xia Y, et al. Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. Am J Pathol. 2010; 177:686-697.
67. Verway M, Behr MA, White JH. Vitamin D, NOD2, autophagy and Crohn's disease. Expert Rev Clin Immunol. 2010;6:505-508.
68. Polidoro L, Properzi G, Marampon F, et al. Vitamin D protects human endothelial cells from H(2)O(2) oxidant injury through the Mek/Erk-Sirt1 axis activation. J Cardiovasc Transl Res. 2013;6:221-231.
69. Cantorna MT. Why do T cells express the vitamin D receptor? Ann N Y Acad Sci. 2011;1217:77-82.
70. Konijeti GG, Boylan MR, Song Y, et al. Sa1779 vitamin D modulates t cell-mediated immunity: results from a randomized controlled trial of lowdose and high-dose vitamin D3. Gastroenterology. 2014;146:S-294.
71. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007;8:5.
72. Simmons JD, Mullighan C, Welsh KI, et al. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut. 2000;47:211-214.
73. Eloranta JJ, Wenger C, Mwinyi J, et al. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics. 2011;21:559-564.
74. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35:308-316.
75. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis. 2013;19:1921-1927.
76. Zator ZA, Cantu SM, Konijeti GG, et al. Pretreatment 25-hydroxyvitamin D levels and durability of anti-Dumor necrosis factor-Alpha therapy in inflammatory bowel diseases. JPEN J Parenter Enteral Nutr. 2014;38:385-391.
77. Jorgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease-A randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377-383.
78. Miheller P, Muzes G, Hritz I, et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis. 2009;15:1656-1662.
79. Mathur J, Mills P, Naing S, et al. Su1385 supplementation of vitamin D3 (cholecalciferol) in patients with ulcerative colitis and hypovitaminosis D: a prospective randomized trial. Gastroenterology. 2014;146:S-454.
80. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985;76:1536-1538.
81. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin Dial. 2007;20:316-324.
82. Xia S, Xia X, Wang W, et al. Associations of ulcerative colitis with vitamin D receptor gene polymorphisms and serum levels of 25-hydroxyl vitamin D [in Chinese]. Zhonghua Yi Xue Za Zhi. 2014;94:1060-1066.
83. Klein S, Meyers S, O'Sullivan P, et al. The metabolic impact of active ulcerative colitis. Energy expenditure and nitrogen balance. J Clin Gastroenterol. 1988;10:34-40.
84. Hebuterne X, Filippi J, Al-Jaouni R, et al. Nutritional consequences and nutrition therapy in Crohn's disease. Gastroenterol Clin Biol. 2009;33 (suppl 3):S235-S244.
85. Campos FG, Waitzberg DL, Teixeira MG, et al. Inflammatory bowel diseases: principles of nutritional therapy. Rev Hosp Clin Fac Med Sao Paulo. 2002;57:187-198.
86. Yoon SS, Sun J. Probiotics, nuclear receptor signaling, and antiinflammatory pathways. Gastroenterol Res Pract. 2011;2011:971938.
87. Sun J. Vitamin D and mucosal immune function. Curr Opin Gastroenterol. 2010;26:591-595.
88. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21:1559-1573.
89. D'Haens GR, Sartor RB, Silverberg MS, et al. Future directions in inflammatory bowel disease management. J Crohns Colitis. 2014;8:726-734.
90. Bamias G, Cominelli F. Novel strategies to attenuate immune activation in Crohn's disease. Curr Opin Pharmacol. 2006;6:401-407.